AIM Vaccine Completes Phase III Trials for High-Efficiency Diploid Rabies Vaccine with Superior Efficacy
Key Insights
AIM Vaccine (search) has successfully completed Phase III clinical site work for its iterative process high-efficiency diploid rabies vaccine, marking a significant milestone toward commercialization.
Animal studies demonstrate the vaccine generates high levels of protective antibodies and significantly outperforms existing marketed diploid rabies vaccines under the same dosage conditions.
The vaccine addresses technical bottlenecks of traditional diploid rabies vaccines by optimizing purification processes and improving virus titer and yield.
AIM Vaccine (search) (06660.HK) announced the successful completion of Phase III clinical site work for its iterative process high-efficiency diploid rabies vaccine on January 15, 2026. The milestone positions the company to advance toward commercialization of what the company describes as a breakthrough in rabies vaccine technology with superior efficacy compared to existing market products.
Enhanced Efficacy and Flexible Administration
Animal studies demonstrate that AIM's vaccine generates high levels of protective antibodies after immunization, significantly outperforming existing marketed diploid rabies vaccines under the same dosage conditions. The vaccine supports flexible administration methods including both "five-dose" and "four-dose" regimens, providing healthcare providers with treatment options.
The enhanced performance represents a significant advancement over traditional diploid rabies vaccines, which have historically faced limitations in virus titer and yield. AIM's iterative process has addressed these technical bottlenecks through optimized and innovative purification processes, resulting in improved product quality and safety.
Manufacturing Capabilities and Market Positioning
AIM has constructed a manufacturing workshop that fully meets international standards and has completed production of samples for commercial-scale Phase III clinical trials. This infrastructure demonstrates the company's capacity for large-scale production of the vaccine.
The diploid rabies vaccine market commands premium pricing due to its use of human diploid cells, which provide natural safety advantages over traditional Vero cell rabies vaccines. Currently, diploid rabies vaccines are priced 3 to 5 times higher than Vero cell alternatives, offering greater product added value for manufacturers.
Strategic Product Portfolio
AIM's approach to the rabies vaccine market encompasses a comprehensive product matrix ranging from traditional Vero cell vaccines to diploid rabies vaccines, iterative serum-free rabies vaccines, and mRNA vaccines. This multi-layered strategy establishes technical barriers and competitive advantages in a market characterized by severe homogenization.
Market Outlook
China represents the largest rabies vaccine market globally. According to China Insights Consultancy statistics, the market is expected to reach RMB14.8 billion by 2030, driven by product updates and increased rabies vaccine coverage. The vaccine industry is currently transitioning from "scale expansion" to "value competition," positioning differentiated products like AIM's iterative vaccine for enhanced market performance.
Analysts anticipate that as multiple iterative rabies vaccine products launch, AIM will establish a product matrix covering different price ranges and demand scenarios, achieving growth through both technology premiums and scale effects in domestic and international markets.